**Care Checklist-2016**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Items** | **Case 1** | **Case 2** | **Case 3** | **Case 4** | **Case 5** | **Case 6** | **Case 7** |
| Age(years) | 44 | 41 | 54 | 42 | 39 | 37 | 33 |
| Gender | Male | Female | Male | Male | Female | Female | Female |
| Past disease history  | Hypertension,Fatty liver | Chronichepatitis B | HepatitisB carrier | None | None | None | None |
| Initial symptom | Right frontalmass | Left orbital swelling | Pulmonary infection | Bone pain | Superciliary arch pain, hypopsia | Chest, low back and leg pain | Low back pain |
| MM type | IgG-κ | k light chain | IgG-κ | IgG-κ | IgG-κ | k light chain | IgG-κ |
| DS stage | IA | IIIA | IIIA | IIIB | IIIA | IIIB | IIIA |
| ISS stage | I | I | II | III | I | III | II |
| FISH test | Normality | No testing | No testing | Normality | 1q21+ | 1q21+ | No testing |
| D1 time | 2018.11 | 2018.4 | 2011.9 | 2007.12 | 2010.2 | 2011.1 | 2014.7 |
| Initial treatment | Surgical resection, VRD and lenalidomide maintenance therapy  | Surgical resection and radiotherapy | T-CAD and lenalidomide maintenance therapy | Surgical resection, T-CAD and thalidomide maintenance therapy | Surgical resection, radiotherapy， T-CAD, BAD, B-CEVAD and thalidomide maintenance therapy | T-CAD,BAD and thalidomide maintenance therapy | Surgical resection and CAD |
| D2 time | 2019.5 | 2018.4 | 2013.10 | 2011.8 | 2010.2 | 2015.2 | 2018.11 |
| Treatment | VRD and lenalidomide maintenance therapy | PDD and lenalidomide maintenance therapy | ,BAD and lenalidomide maintenance therapy | Surgical resection and T- CAD | T-CAD, BAD and thalidomide maintenance therapy  | BAD,T-CAD and thalidomide maintenance therapy | R-DECP .BEDand lenalidomide maintenance therapy |
| Outcome | Survival | Died | Died | Died | Died | Died | Survival |
| PFS | 18 months | 13 months | 33 months | 44 months | 33 months | 36 months | 24 months |
| OS | 18 months | 25 months | 36 months | 127 months | 48 months | 60 months | 71 months |

**Note:** D1,multiple myeloma;D2,orbital EMD; PD, disease progression; ISS, International Staging System;

FISH, fluorescence in situ hybridization; VRD :Bortezomib,Lenalidomide and Dexamethsone;

BAD regimen(Bortezomib,Doxorubicin and Dexamethsone);

CAD : Ifosfamide,Epirubicin or Piraubicin and Dexamethsone ;T-CAD :thalidomide and CAD;

B-CEVAD: Bortezomib,Etoposide,ifosfamide, Vindesine sulfate , Epirubicin,and Dexamethsone;

BED regimen:(Bortezomib, Etoposide and Dexamethsone;CR: complete remission; PR: partial remission.